Aardvark Therapeutics, Inc. (AARD) Files Proxy Statement Ahead of Shareholder Meeting
Filing Details Aardvark Therapeutics, Inc. (NASDAQ:AARD) filed a definitive proxy statement (DEF 14A) with the Securities and Exchange Commission on July 10, 2026. The Healthcare…
Read more
